Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs - Wikidata - wikimedia - TriplyDB

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

http://www.wikidata.org/entity/Q28203992

about

sameAs

5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice Patient considerations in the management of chronic constipation: focus on prucalopride Persistent constipation and abdominal adverse events with newer treatments for constipation.Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study.Prucalopride: the evidence for its use in the treatment of chronic constipation.Prucalopride for constipation.Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties.Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.The effects of prucalopride on postoperative ileus in guinea pigs.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Effects of 5-HT2B, 5-HT3 and 5-HT4 receptor antagonists on gastrointestinal motor activity in dogs Measurement of Gastrointestinal and Colonic Motor Functions in Humans and Animals Novel pharmacological therapies for management of chronic constipation.Prucalopride: a new drug for the treatment of chronic constipation.Investigational agents for the irritable bowel syndrome.Existing and emerging therapies for irritable bowel syndrome.Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation.Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments.Prucalopride: a review of its use in the management of chronic constipation.New pharmacological treatment options for chronic constipation.Efficacy and safety of prucalopride in adults and children with chronic constipation.Prucalopride: A Review in Chronic Idiopathic Constipation.Prucalopride succinate for the treatment of constipation: an update.Gastrointestinal dysmotility disorders in critically ill dogs and cats.Effect of enterokinetic prucalopride on intestinal motility in fast rats.Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group.The novel, potent and highly selective 5-HT4 receptor agonist YH12852 significantly improves both upper and lower gastrointestinal motility.An update on prucalopride in the treatment of chronic constipation.The enteric serotonergic system is altered in patients with diverticular disease.Colonic electrical stimulation: potential use for treatment of delayed colonic transit.5-HT4 receptors located on cholinergic nerves in human colon circular muscle.Investigation of serotonin receptors in the isolated penile bulb of rats.YH12852, a potent and highly selective 5-HT4 receptor agonist, significantly improves both upper and lower gastrointestinal motility in a guinea pig model of postoperative ileus.

P2860

Q24564961-E4B0CE32-A3A3-498E-BFC3-EA1A910DBE0B Q26741304-7E2D0F35-AA8F-47E2-BC62-DCAEB4168075 Q33468562-A37023BE-8574-4249-8F2B-53EEF6F25BB5 Q33695505-0BCE98B3-C1B2-411F-9BC8-723C9ABC2B8F Q33816342-D2DB69E2-1F1B-46AD-A99E-8C516071A5B3 Q33973983-086E976E-908E-44CB-AD1D-580811C9B014 Q34094831-8C7F9C10-5FC7-40AA-8116-A6EDAA6581D4 Q34146166-981DA435-01B1-4953-8EA0-5AE2EB38A1F5 Q34166903-B57431A5-A73D-411D-A6B8-4914E614DBAC Q35025872-7C7F6EE3-E7ED-4934-AD4B-E7F5E4E695FC Q35026383-9BC1BF2F-3310-4D2A-90AB-573E9D974C0E Q36872925-6E138535-475A-414E-8C34-0C7793FB4587 Q37164063-4276BF1E-128B-4013-BEA1-1C648B650560 Q37241590-CD70099C-E756-47FD-8C96-B085A6163D8F Q37261844-8C8C40C9-678F-4B20-94AC-3ABCB2324DA9 Q37394824-57AF32C8-1919-4BA8-AE5A-B53D033B4820 Q37578493-73E3B832-6F9E-44EE-88CB-72A718B09066 Q37788218-A7C8BEBF-96FE-4255-AABD-B10045245A38 Q37857849-1DBD18C8-656E-46FA-8E8C-8DD229AEF7AB Q38044067-9EE9BA2F-8026-497A-9826-94C496389D3A Q38083079-7B126A1F-CD8A-4075-8439-B100711254CC Q38160205-402D8C0F-97C1-495C-9F21-AA577E79528D Q38198743-4B7505AE-8CD0-46A7-95FC-F18F52197371 Q38300258-CF3CCF36-1861-4338-B5C4-73E7E456AE82 Q38656212-CEA5D493-1FE6-4699-8899-D4E3CD17038C Q38662841-1A465A9E-6975-4AB7-B0CA-0453B241393F Q38715379-FBE17942-D5D3-4FF4-8E2F-5124A7AAE315 Q42079920-8A54404B-F1ED-4CD4-AC3B-9F8A8FEE1277 Q43062741-9BDDD064-A898-4332-A89A-CBACF2F0BE5B Q43366415-C3516EF6-DFD1-4AC5-A744-CD580D0C5ADC Q45044943-1BEAE1FA-95D2-409A-AB98-4D4D0EF7FB6A Q46066776-245E38BB-1098-4F29-96D3-D9A51008E7D9 Q46194560-E96CFB27-5C8C-4AF6-8608-C7051675133B Q46509742-799C9F7A-EDAD-4EBD-B5AA-17D3E0867EC2 Q46983906-6A2C06A4-B6C4-44B0-B879-B7F70AA405FA Q47295262-F875F39F-FBD5-4402-8BE7-3EC0477DFFA0

P2860

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

http://www.wikidata.org/entity/Q28203992

description

2001 nî lūn-bûn

@nan

2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

@ast

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

@en

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

@nl

type

label

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

@ast

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

@en

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

@nl

prefLabel

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

@ast

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

@en

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

@nl

P1433

Q28203992-47A5CADB-58D4-496D-98C2-9457D22DB9F7

P1476

Q28203992-8F1A2FAD-AC9F-445E-B08C-CB0427F724C2

P2093

Q28203992-23BAE033-025B-43C5-A80F-6F818B628A5D

Q28203992-CE0B9060-CED6-4FA9-A655-5EF5A940FFC7

Q28203992-ECC130A0-68DE-408F-A2C1-82D196FB3A41

P2860

Q28203992-1D4D109C-D7DE-4EF2-911A-A62CDC44DF79

Q28203992-34DA8655-7F49-41B7-81A3-7D3C1C7B6601

Q28203992-71A7AB4E-31F6-4FAB-9D03-9454206B1D8C

Q28203992-A70EC00C-0B2E-45A4-ABEA-4D50A659A6D4

Q28203992-BAB80A16-1903-4EDA-AD71-BD61147B821D

Q28203992-CF22BF7C-DD6D-4D16-94A2-C70BA0177246

Q28203992-F0683CAE-1AB8-438D-98DB-581535228636

P304

Q28203992-6221BE53-DA50-4656-BE45-EAE37A5238BE

P31

Q28203992-5F4AB2D1-D796-4C39-B295-63520612DE98

P3181

Q28203992-A726EBC2-23F1-4E34-8B5F-0427E1E415F4

P356

Q28203992-0157677B-46D5-4984-BC42-97D6B2906EAB

P407

Q28203992-6D921ED3-9FD2-4B11-AF0A-B9A0E47A8B62

P433

Q28203992-E89D28E5-75A7-4F7C-AB7E-3CA6FD9CC83D

P478

Q28203992-54482A10-D99A-46CA-A888-A8B001571DB8

P577

Q28203992-C1E6E2A0-85D5-4D59-A169-E1438295C5D1

P5875

Q28203992-4D13C059-EDCD-4CFD-86D2-5902336221F5

P698

Q28203992-CB9BC2D8-3F71-4D34-8B65-7FB1A48FCBF5

P3181

P356

J.1365-2982.2001.00280.X

P1433

Neurogastroenterology and Motility

P1476

Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs

@en

P2093

J A Schuurkes

http://www.w3.org/2001/XMLSchema#string

M R Briejer

http://www.w3.org/2001/XMLSchema#string

N H Prins

http://www.w3.org/2001/XMLSchema#string

P2860

The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.

Colonic mass movements in idiopathic chronic constipation.

5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle

Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle.

Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers.

Stimulation of cyclic AMP formation in the circular smooth muscle of human colon by activation of 5-HT4-like receptors

Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle

P304

465-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1314879

http://www.w3.org/2001/XMLSchema#string

P356

10.1046/J.1365-2982.2001.00280.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11658521

http://www.w3.org/2001/XMLSchema#string

P698

11696108

http://www.w3.org/2001/XMLSchema#string